AzTrials
AzTrials

MalnutritionNCT05083637

L-Carnitine Supplementation, Rate of Weight Gain and EED in Children With SAM

A study testing L- carnitine oral solution in people with Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Burden: Globally, an estimated 14.3 million under-5 children are severely malnourished. Two-thirds of them live in Asian countries, including Bangladesh. Acute malnutrition is an underlying cause of nearly half of global deaths in under-5 children despite standardized rehabilitation protocols. Read more about this study

Who is it for?
Ages 9 to 24 months
Conditions the study is for
Malnutrition
What is being tested?
L- carnitine oral solution
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
98 participants
Where
1 siteBangladesh
Study dates
19 Oct 2021to 30 Mar 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 9 to 24 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Diarrheal children with SAM aged 9-24 months
  • Signed informed consent by the guardian/caregivers

Who cannot join

  • Severe sepsis or Septic shock
  • Patients already taking medications containing L- carnitine
  • Children with Tuberculosis
  • Children with congenital defects or chromosomal anomalies
  • Children with a diagnosed case of Thalassemia
  • Children with an active or previous history of convulsion

Trial locations and contacts

1 site in 1 country.

Bangladesh1 site
  • Dhaka Hospital; International Centre for Diarrhoeal Disease Research, Bangladesh

    Dhaka, 1212

Other trials in Bangladesh

About this study

Official title: Role of L-Carnitine Supplementation on Rate of Weight Gain and Biomarkers of Environmental Enteric Dysfunction (EED) in Children With Severe Acute Malnutrition

Background:

Burden:

Read more

Globally, an estimated 14.3 million under-5 children are severely malnourished. Two-thirds of them live in Asian countries, including Bangladesh. Acute malnutrition is an underlying cause of nearly half of global deaths in under-5 children despite standardized rehabilitation protocols. It is also associated with high relapse rates following discharge.

Knowledge Gap:

Malnourished children suffer from deficiencies of several essential nutrients. Studies showed that malnourished children had lower serum carnitine levels and demonstrated its role in the rate of weight gain in children with severe acute malnutrition (SAM). The consequences of nutritional impairment can be perilous if carnitine deficiency is coupled with Environmental Enteric Dysfunction (EED). Recent evidence confirms that EED is characterized by secondary carnitine deficiency in children. Carnitine deficiency leading to EED may cause childhood growth faltering and impaired cognitive development. However, evidence on carnitine status and its consequences in relation to EED in diarrheal children with SAM is very limited in Bangladesh.

Relevance:

Such lack of information regarding the role of L-carnitine in improving the rate of weight gain in malnourished children susceptible to EED is an obstacle in limiting the relapse and adverse consequences of SAM in diarrheal children living in resource-limited countries.

Hypothesis: L- carnitine supplementation for 15 days in children with SAM will improve the rate of weight gain and biomarkers of EED

Objective:

  1. To investigate the role of L-carnitine supplementation on the rate of weight gain among the children with SAM
  2. To investigate the role of L-carnitine supplementation on the duration of the hospital stays
  3. To examine the role of L-carnitine supplementation on EED biomarkers, for instance, myeloperoxidase (MPO), neopterin (NEO), alpha-1 anti-trypsin (A1AT), kynurenine: tryptophan (KT) ratio, and citrulline in children with SAM

Methods: This study will be a double-blinded, placebo-controlled randomized clinical trial

Read the detailed description

Study Design:

Study Site:

This study will be done in the Dhaka Hospital at icddr,b.

Study population:

In this study, the investigator will enroll diarrheal children with SAM aged 9-24 months of both genders attending longer stay units (LSU).

Study duration: 12 months

Screening, Consenting, and Baseline Data Collection:

The research staff ( Field Research Assistant) will screen all the participants within the defined age groups according to the eligibility criteria (Detailed inclusion/exclusion criteria are provided separately below). Then research staff will explain the study in detail, answer any questions from the parent(s), and invite the parent(s) to enroll the child in the study. If the parent(s) are interested in volunteering in the study, the designated staff will proceed to consent consisting of a thorough review of the written consent form in a manner appropriate for the child's parents' literacy level. Prior to signing the consent form, parent(s) will have an opportunity to ask any questions about the study participants fulfilling the eligibility criteria will be brought to the study physician for clinical assessment. If the parent(s) are not sufficiently literate to read and/or sign the consent form, consenting and fingerprint signature will be obtained in the presence of a witness who is not associated with the study. The child's parent(s) will be provided with a copy of the signed consent form. Upon signing a written informed consent, the participant will be enrolled by the study physician.

Randomization:

Participants will be assigned to the intervention or the control arm using permuted block randomization method with concealment to ensure that the allocation is not made before the participant has given their consent and joined the study. A random allocation sequence will be generated using a computerized random allocation system for permuted block randomization to ensure comparable allocation numbers at certain equally spaced points in the sequence of patient assignments. A parallel type of randomization will be used. Reasonably large blocks with variable block sizes will be constructed to reduce the predictability. Random assignment will be prepared in advance by an independent researcher from icddr,b, who has no involvement with the trial.

Anthropometric measurements:

All the measurements will be taken at enrollment and each day when the participants will receive intervention/placebo. End-line anthropometry data will be collected on the 15th day of supplementation. In addition, we will measure anthropometry on the 180th day after the completion of supplementation to observe the long-term effect of the intervention on the rate of weight gain. Trained staff will take all the measures as per the standard operating procedures (SOPs) and keep records in standard CRFs. The Seca weighing scale will be used for weight measurement in kg, and the Seca length board will be used for length measurement in cm. And mid-upper arm circumference (MUAC) will be measured in cm using a non-stretch tape.

Intervention:

The intervention will be given to the child along with the standard of treatment at the nutritional rehabilitation unit (NRU). Detailed information about the investigational product is provided separately below. Children will be monitored daily by trained physicians for any side effects/adverse events (such as nausea, vomiting, diarrhea, rash, urticaria, or any significant changes in clinical status). If any adverse events are observed, children will be treated using appropriate management practices at Dhaka Hospital.

Biological sample collection:

The investigators will collect blood, stool, and urine from the participants at enrolment and at the end of the nutrition intervention. Overall, 5 ml of whole venous blood will be collected aseptically from each of the participants as per the SOPs. The blood biomarkers that will be tested in this study are L-carnitine, Citrulline, KT Ratio, C-reactive protein (CRP), and Alpha-1-acid glycoprotein (AGP). CRP is an acute-phase protein and can be detected during infection. Increased level of AGP in serum indicates systemic tissue injury, inflammation, and infection. Both Citrulline and KT ratios indicate EED in children. The stool will be collected to investigate the concentrations of MPO, NEO, and A1AT in the fecal samples. The investigators will measure L-carnitine levels in the urine samples of each participant. All the assays will be done at icddr,b.

Laboratory Investigation:

The investigators will measure L-carnitine levels in plasma and urine and EED biomarkers in every enrolled patient. Pre and post-test will be done. The pre-test will be on the first day of enrolment, and the post-test will be on the 15th day after the completion of supplementation.

Sample Size Calculation:

The sample size is estimated considering the primary outcome variable. For the primary objective, the investigators have considered an intervention study in Turkey. The study discovered that the mean difference between the rate of weight gain in malnourished children after L-carnitine supplementation was 2.4 (The weight was measured in kg) with a standard deviation of 4.3. Setting the level of confidence at 95% (Z1-α =1.645) and the study power at 80%, the estimated sample size is 49 participants in each group with a 10% attrition rate. So, the total sample size for this study will be 98.

Data Analysis Plan:

Data will be entered into the pre-tested case record forms (CRFs) using Statistical Package for the Social Sciences (SPSS 20.0 version) and finally cleaned with a repeated check. Data will be presented using frequency with percentages for categorical variables. Mean with standard deviation will be used for symmetrical continuous variables. Median with interquartile range will be used for asymmetrical numeric variables. To know the outcome of the intervention in our study children bivariate, crude analyses of the association will be done that will involve Chi-square or Fisher's exact test for comparing differences in proportion and t-tests for numeric variables between the groups. Nonparametric continuous data will be analyzed by Mann-Whitney U-test. Results from all children will be included in the analysis of the study on an intention-to-treat basis. Data from children withdrawn because of failure to respond, or voluntary dropouts will be included in the analysis up to the time of withdrawal. A supplementary analysis excluding the children withdrawn may also be done. A probability of less than 0.05 will be considered statistically significant.

Conditions
Malnutrition
Being tested
L- carnitine oral solution, Placebo
Keywords
Malnutrition, L-Carnitine, Environmental Enteric Dysfunction, Under-5 children, Bangladesh
Medical subject headings
Malnutrition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • L- carnitine oral solutionDrug

    Also called Levocarnitine oral solution

    The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up

  • PlaceboOther

    The placebo formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up

Study groups in NCT05083637
Study groupRoleWhat they receive
Intervention ArmActive comparatorChildren randomized to this arm will receive L- carnitine oral solution (100mg/ml) (Generic Name) with the dosage- 100 mg/kg/day, divided into 3 doses per day for 15 days.
Receives: Drug: L- carnitine oral solution
Control ArmPlacebo comparatorChildren randomized to this arm will receive placebo in same quantity, divided into 3 doses per day for 15 days.Placebo solution will be identical in appearance, smell and taste to the active preparation (L-carnitine syrup) with no therapeutic value.
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of weight gain

    The rate of weight gain (g/kg/day) will be calculated by using the formulae below:

    [{Weight on completion of study - Weight on enrolment (or at no edema) (g)} / {Total duration (in days) * weight on enrolment in kg}]

    Measured: Baseline to 15th day of treatment

Secondary outcomes (2)
  1. Duration of hospital stays

    It will be assessed by comparing duration of total hospital stay between the two arm

    Measured: Baseline to 15 days of treatment

  2. EED biomarkers [myeloperoxidase (MPO), neopterin (NEO), alpha-1 anti-trypsin (A1AT), kynurenine: tryptophan (KT) ratio, and citrulline]

    Biological sample will be analyzed using ELISA- based measurements

    Measured: Baseline to 15 days of treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Oct 2021
  2. Study start19 Oct 2021
  3. Primary completion30 Mar 2023
  4. Study completion30 Mar 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
98 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05083637
Sponsor's protocol ID
PR-21046
Status last verified
Jan 2023
First submitted
5 Oct 2021
Last updated
7 Mar 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: After the end of the study, data will be analyzed as per the defined data analysis plan on the protocol. Study results will be shared with other researchers by journal publications, conferences proceedings, and dissemination programs

Publications

  • Alp H, Orbak Z, Akcay F, Tan H, Aksoy H. Plasma and urine carnitine levels and carnitine supplementation in children with malnutrition. J Trop Pediatr. 1999 Oct;45(5):294-6. doi: 10.1093/tropej/45.5.294.

    PubMed 10584472
  • Alam J, Fahim SM, Islam MR, Alam MA, Gazi MA, Ahmed T. Effects of L-Carnitine Supplementation on the Rate of Weight Gain and Biomarkers of Environmental Enteric Dysfunction in Children with Severe Acute Malnutrition: A Double-Blind Randomized Controlled Clinical Trial. J Nutr. 2024 Mar;154(3):949-961. doi: 10.1016/j.tjnut.2024.01.031. Epub 2024 Feb 6.

    PubMed 38331348
  • Alam J, Islam MR, Fahim SM, Gazi MA, Ahmed T. Role of L-Carnitine supplementation on rate of weight gain and biomarkers of Environmental Enteric Dysfunction in children with severe acute malnutrition: A protocol for a double-blinded randomized controlled trial. PLoS One. 2022 Sep 30;17(9):e0275291. doi: 10.1371/journal.pone.0275291. eCollection 2022.

    PubMed 36178918

Questions about this trial

What is this clinical trial studying?

A study testing L- carnitine oral solution in people with Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of weight gain (time frame: Baseline to 15th day of treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05083637, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in